Physician profile
Richard S Sinclair
NPI 1396184040
$1,655.86
in general payments reported to CMS, 2019-2025
15 companies · $71.72 in 2025
The $71.72 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $116 · 2021: $452 · 2022: $261 · 2023: $231 · 2024: $57.90 · 2025: $71.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $360.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $657.46 | 2021-2025 | Vraylar |
| Corium, LLC | $206.91 | 2021-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $145.96 | 2019-2021 | |
| Allergan, INC. | $118.06 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $78.22 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $70.78 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.78 | 2019-2022 | |
| Lundbeck LLC | $53.47 | 2019-2023 | Rexulti |
| Supernus Pharmaceuticals, INC. | $51.29 | 2021 | |
| Sunovion Pharmaceuticals INC. | $50.38 | 2021 | |
| Janssen Pharmaceuticals, INC | $42.62 | 2019-2021 | |
| Neos Therapeutics, LP | $39.55 | 2019-2025 | Exxua |
| Shire North American Group INC | $38.13 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $35.39 | 2019-2020 | |
| Tris Pharma INC | $13.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Sinclair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.